– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted pro

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeti

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinso

Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs ba

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immu

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the

Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (N

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC pla

Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the pri

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about

Arvinas (NASDAQ: ARVN) said it is concentrating resources on its early-stage oncology and neurology

Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weigh

Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the pri

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pi

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensu

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the

Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensu

– Secured the first-ever regulatory approval of a PROTAC (a type of  heterobifunctional protein degr

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology co

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted

Stephens & Co. analyst Sudan Loganathan reiterates Arvinas (NASDAQ:ARVN) with a Overweight an

Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo